<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041639</url>
  </required_header>
  <id_info>
    <org_study_id>IM-T-hMN14-03</org_study_id>
    <nct_id>NCT00041639</nct_id>
  </id_info>
  <brief_title>Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer</brief_title>
  <official_title>A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in&#xD;
      the treatment of pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date>December 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMN14 (labetuzumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Disease Characteristics:&#xD;
&#xD;
          -  Patients with a documented histologic or cytologic diagnosis of a pancreatic&#xD;
             malignancy&#xD;
&#xD;
          -  Patients with recurrent, advanced and/or metastatic disease, who have either failed&#xD;
             standard therapy or are not eligible for any alternate therapies of higher therapeutic&#xD;
             priority.&#xD;
&#xD;
          -  Patients with at least one identified (confirmed) and measureable tumor site.&#xD;
&#xD;
        Prior/Concurrent Therapy:&#xD;
&#xD;
          -  Surgery: Patients are excluded if they have had major surgery either during or within&#xD;
             four weeks prior to study entry.&#xD;
&#xD;
          -  Chemotherapy: Patients must have failed standard therapy or are not eligible for any&#xD;
             alternate therapies of higher therapeutic priority.&#xD;
&#xD;
          -  Biologic Therapy: Patients who have received a chimeric, CDR-grafted (humanized), or&#xD;
             human IgG will be eligible provided pre-study evaluations demonstrate no significant&#xD;
             reactivity with hMN14 IgG (i.e., HAHA)&#xD;
&#xD;
          -  Radiotherapy: No prior radiotherapy within four weeks of study entry. No prior&#xD;
             external beam irradiation to a field that includes more than 30% of the red marrow. No&#xD;
             prior radiation to maximal tolerable levels for any critical organ (e.g., 3,000 cGy&#xD;
             for the liver; 2,000 cGy for the lungs and kidneys).&#xD;
&#xD;
          -  Other: Any experimental therapy (i.e., drugs, biologics, procedures) for the primary&#xD;
             malignancy, either during or within four weeks prior to study entry.&#xD;
&#xD;
        Patient Characteristics/Inclusion Criteria:&#xD;
&#xD;
          -  Performance Status: Patients with a Karnofsky performance status &gt; 70% (or equivalent,&#xD;
             ECOG 0-1) and an expected survival rate of at least 3 months&#xD;
&#xD;
          -  Hematopoietic: Hemoglobin &gt; 10g/dL; WBC &gt; 3000 per mm3; Granulocyte count &gt; 1500 per&#xD;
             mm3; platelet count &gt; 100,000 per mm3&#xD;
&#xD;
          -  Hepatic: Total bilirubin &lt; 1.5 times the institutional upper limit of normal (IULN);&#xD;
             AST or ALT &lt; 2 X IULN&#xD;
&#xD;
          -  Renal: Creatinine &lt; IULN&#xD;
&#xD;
          -  Cardiovascular: Patients with LVEF &gt;/= 50% by required MUGA/2D-ECHO study&#xD;
&#xD;
          -  Pulmonary: Patients with DF and FEV1 &gt;/= 60 % by required Pulmonary Function Tests&#xD;
&#xD;
          -  Gastrointestinal:Patients with severe anorexia or other related symptomology are&#xD;
             excluded&#xD;
&#xD;
          -  Central Nervous System: Patient with known metastatic disease to the CNS are excluded&#xD;
&#xD;
          -  Other: Patients who have had a prior imaging study with a murine antibody may be&#xD;
             included. Patients agreeing to use a medically effective method of contraception&#xD;
             during and for a period of three months after the treatment period. A pregnancy test&#xD;
             will be preformed on each premenopausal female of childbearing potential immediately&#xD;
             prior to entry into the study. Patients able to understand and give written informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Wegener, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Cancer Center</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Medical Center</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-2799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultaet der Charit√© Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2004</verification_date>
  <study_first_submitted>July 11, 2002</study_first_submitted>
  <study_first_submitted_qc>July 12, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2002</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Pancreatic Carcinoma</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>Pancreas Cancer</keyword>
  <keyword>Pancreatic Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labetuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

